BCYC News and Press, Bicycle Therapeutics plc From 09/06/22

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced that management will participate in a fireside chat at the Morgan S...

Cowen launched its coverage on oncology-focused biotech Bicycle Therapeutics ( NASDAQ: BCYC ) on Wednesday, arguing that the company’s therapeutic platform of bicycle toxin conjugates (BTC) can outshine another cancer drug class called antibody-drug conjugates (ADC). ...

Bicycle Therapeutics press release ( NASDAQ: BCYC ): Q2 GAAP EPS of -$0.90 misses by $0.04 . Revenue of $4.38M (+144.7% Y/Y) beats by $0.69M . For further details see: Bicycle Therapeutics GAAP EPS of -$0.90 misses by $0.04, revenue of $4.38M beats by $0....

- Continued clinical progress across pipeline, including dosing of the first patient in expansion cohorts of Phase I/II study of BT5528 - Expansion of Genentech exclusive strategic collaboration, triggering a $10 million payment to Bicycle in Q3 - Cash and cash equival...

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced that an article highlighting data using tris-Gold complexes to ...

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced that an article highlighting preclinical data from BT7480, a Bicy...

Bicycle Therapeutics ( NASDAQ: BCYC ) will get $10M from Genentech as the Roche ( OTCQX:RHHBY ) ( OTCQX:RHHBF ) unit exercised its second option to begin a new program under a collaboration to discover, develop and sell novel immuno-oncology therapies. The two ...

Genentech exercises second option to initiate an additional program under the 2020 collaboration agreement Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( ...

BCYC was founded by a Nobel Prize winner. Hopefully, that will not be its only claim to fame. However, convincing proof of concept is another year away. Bicycle Therapeutics plc ( BCYC ) is co-founded by Nobel Prize winning molecular biologist Dr. Greg Winter, who is...

Completed Phase I dose escalation; results expected in 3Q22 Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today annou...